InterCure (NASDAQ:INCR) Shares Up 1.5% – What’s Next?

InterCure Ltd. (NASDAQ:INCR) shares shot up 1.5% on Monday . The company traded as high as $0.9999 and last traded at $0.9760. 8,424 shares were traded during trading, a decline of 57% from the average daily volume of 19,470 shares. The stock had previously closed at $0.9618.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded InterCure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

InterCure Stock Performance

The firm has a market cap of $53.37 million, a price-to-earnings ratio of 32.53 and a beta of 1.40. The firm’s 50 day moving average is $0.98 and its 200-day moving average is $0.89. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.97 and a current ratio of 1.48.

InterCure (NASDAQ:INCR) last posted its earnings results on Thursday, April 30th. The company reported ($0.10) EPS for the quarter. The business had revenue of $23.15 million for the quarter.

About InterCure

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.